Posted by Michael Wonder on 16 Dec 2019
Avadel Pharmaceuticals receives U.S. FDA approval for Nouress (AV001), a cysteine hydrochloride injection for treating neonate patients requiring total parental nutrition
16 December 2019 - USPTO issues Orange Book-listed patent for Nouress.
Avadel Pharmaceuticals announced today that the U.S. FDA has approved Nouress (AV001), a cysteine hydrochloride injection, a critical drug for treating neonatal patients requiring total parenteral nutrition.
In addition, Avadel announced today that the United States Patent and Trademark Office (USPTO) recently issued United States Patent No. 10,493,051 covering cysteine solutions, including the approved Nouress product. This patent is listed in the Orange Book for Nouress and is set to expire in March of 2039. Avadel has additional U.S. patent applications pending for Nouress.
